Evidence map›Paper›PMID 40312344›Full record

ArticleNature communications2025

Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy.

Zhixiang Chen, Harshil Dhruv, Xuqing Zhang, Rohan Kalyan Rej, Longchuan Bai, Donna McEachern, Paul Kirchhoff, Rakesh Nagilla, Larry J Jolivette, Cory T Rice and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Evolving CRBN ligands enhance the drug-like properties of protein degraders.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zhixiang Chen *Rogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0009-0007-4526-1588
Harshil Dhruv *SK Life Sciences Labs, King of Prussia, PA, USA.
Xuqing Zhang *SK Life Sciences Labs, King of Prussia, PA, USA.
Rohan Kalyan Rej *Rogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-0904-9137
Longchuan Bai *Rogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA.
Donna McEachernRogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA.
Paul KirchhoffRogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA.
Rakesh NagillaSK Life Sciences Labs, King of Prussia, PA, USA.
Larry J JolivetteSK Life Sciences Labs, King of Prussia, PA, USA.
Cory T RiceSK Life Sciences Labs, King of Prussia, PA, USA.
Peter OrthSK Life Sciences Labs, King of Prussia, PA, USA.ORCID http://orcid.org/0000-0002-8475-682X
Corey O StricklandSK Life Sciences Labs, King of Prussia, PA, USA.
E Scott PriestleySK Life Sciences Labs, King of Prussia, PA, USA.ORCID http://orcid.org/0000-0001-8390-1143
Helai P MohammadSK Life Sciences Labs, King of Prussia, PA, USA.
Meilin WangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Bo WenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Duxin SunDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-6406-2126
Zhihua SuiSK Life Sciences Labs, King of Prussia, PA, USA.
Shaomeng WangRogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and, Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, USA. shaomeng@umich.edu.ORCID http://orcid.org/0000-0002-8782-6950

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
NCI NIH HHS P30 CA046592U.S. Department of Health & Human Services | National Institutes of Health (NIH) P30CA046592
6 · The paper itself

Abstract

IKZF2 (Helios) is a transcription factor that is selectively expressed by Tregs and is essential for preserving the function and stability of Tregs in the tumor microenvironment (TME), where it suppresses the anti-tumor immune response. Targeted IKZF2 degradation by small molecules represents a promising strategy for the development of a new class of cancer immunotherapy. Herein, we describe the discovery of PVTX-405, a potent, effective, highly selective, and orally efficacious IKZF2 molecular glue degrader. PVTX-405 degrades IKZF2 (DC

Indexed as

Ikaros Transcription FactorImmunotherapyNeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleHumansInterleukin-2MiceT-Lymphocytes, RegulatoryTumor MicroenvironmentIkaros Transcription FactorInterleukin-2

Identifiers

PMID40312344
PMCPMC12046021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.